Oxybutynin is an antimuscarinic agent that reduces detrusor muscle activity, relaxing the bladder and preventing the urge to void. Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide.
- Mechanism
- Curator reviewed · 3 references
Oxybutynin acts to relax the bladder by inhibiting the muscarinic action of acetylcholine on smooth muscle, and not skeletal muscle. The active of oxybutynin is metabolite is N-desethyloxybutynin. It competitively inhibits the postganglionic type 1, 2 and 3 muscarinic receptors. The above actions lead to increased urine capacity in the bladder, decreasing urinary urgency and frequency. In addition, oxybutynin delays the initial desire to void.
- Primary indication
- Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency.Curator reviewed · 3 structured indications
- Formula / weight
- C22H31NO3 · 357.4864 g/mol (avg)
- First approval
- Canada, 1998 · United States, 1975 · European Union, 2016
- Brand names
Resolves to
XIQVNETUBQGFHX-UHFFFAOYSA-NSMILESCCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Oxybutynin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account